Document Detail


Lopinavir/ritonavir combination and total/HDL cholesterol ratio.
MedLine Citation:
PMID:  15780417     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVES: To describe the evolution of the lipidic profile among LPV/r treated patients in a 'real life' situation. METHODS: Lipids measurements at LPV/r initiation time and every 3 months, and pharmacological measurements at M3 and M6 were collected retrospectively in 142 patients attending our clinic. Dyslipidaemia was defined as total cholesterol > or =6.2 mmol/l, HDL-cholesterol > or =1 mmol/l, total/HDL-cholesterol ratio > or =6.5 and triglycerides > or =2.3 mmol/l. RESULTS: Eighty-nine percent of patients had previously received a regimen with protease inhibitors, 4% were treatment naive. At baseline, 17% of patients had high total cholesterol, 49% high triglycerides, 63% low HDL-cholesterol, 25% a high total/HDL-cholesterol ratio. At M12, the mean HDL-cholesterol increase per patient was 21%. Lipids levels significantly increased over the study period, as early as the 3rd month (6th month for ratio) and continuously until the 12th month. Among the patients with available LPV/r plasma determinations at M3, a higher lopinavir residual concentration was observed in those with high triglycerides (6.78 vs 3.02 mg/l, p = 0.05) as, at M6, in those with an elevated ratio (9.19 vs 0.96 mg/l, p = 0.02). CONCLUSIONS: Those results suggest that LPV/r may induce a significant rise in the total/HDL-cholesterol ratio, despite an increase in HDL-cholesterol levels. The association between triglycerides and total/HDL-cholesterol ratio elevated levels and high residual concentrations of lopinavir may also argue for systematic drug monitoring.
Authors:
Laure Valerio; Eric Fontas; Christian Pradier; Thibaud Lavrut; Rodolphe Garraffo; Brigitte Dunais; Eric Cua; Pierre Dellamonica
Related Documents :
2455187 - Prazosin improves atherogenic index and inhibits the deleterious effect of dihydrochlor...
15246907 - Accuracy of the triglyceride to high-density lipoprotein cholesterol ratio for predicti...
3279847 - Effect of ethanol dose on low density lipoproteins and high density lipoprotein subfrac...
15738977 - Hdl as a target in the treatment of atherosclerotic cardiovascular disease.
8072927 - The effect of varying levels of dietary vitamin a on immune response in the chick.
2059897 - Influence of physical activity and dietary restraint on resting energy expenditure in y...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  The Journal of infection     Volume:  50     ISSN:  0163-4453     ISO Abbreviation:  J. Infect.     Publication Date:  2005 Apr 
Date Detail:
Created Date:  2005-03-22     Completed Date:  2005-05-27     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  7908424     Medline TA:  J Infect     Country:  England    
Other Details:
Languages:  eng     Pagination:  229-35     Citation Subset:  IM    
Affiliation:
Department of Public Health, Hôpital de l'Archet I, Centre Hospitalier Universitaire, Route de Saint Antoine de Ginestière, BP 3079-06202 Nice Cedex 3, France.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Cholesterol / blood
Cholesterol, HDL / blood
Drug Combinations
Female
HIV Infections / blood,  drug therapy
HIV Protease Inhibitors / adverse effects*
Humans
Hyperlipidemias / chemically induced*
Male
Middle Aged
Pyrimidinones / administration & dosage,  adverse effects*,  blood
Retrospective Studies
Ritonavir / administration & dosage,  adverse effects*
Time Factors
Chemical
Reg. No./Substance:
0/Cholesterol, HDL; 0/Drug Combinations; 0/HIV Protease Inhibitors; 0/Pyrimidinones; 0/Ritonavir; 192725-17-0/lopinavir; 57-88-5/Cholesterol

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Clinical outcomes of HIV-HCV co-infection in a large cohort of hemophiliac patients.
Next Document:  Fusobacteriosis presenting as community acquired pneumonia.